Ferroptosis is a new type of programmed cell death caused by the accumulation of iron-dependent lipid peroxides, and it plays a role in the occurrence and progression of diverse diseases. Diabetic cardiomyopathy (DCM), a serious cardiovascular complication in patients with diabetes, eventually progresses to refractory heart failure (HF), which increases the risk of hospitalization for HF and cardiovascular death in patients with diabetes. Despite glycemic control, effective strategies to prevent DCM onset are currently lacking. Accumulating evidence suggests that ferroptosis is involved in oxidative stress, inflammation, and abnormal autophagy in diabetic myocardium, which plays an important role in myocardial apoptosis, hypertrophy, and cardiac fibrosis. The inhibition of ferroptosis can relieve DCM. Presently, ferroptosis inhibitors have been broadly suggested for the treatment of iron overload-related cardiomyopathy. This article reviewed relevant studies to offer a new therapeutic target for DCM.
第一作者机构:[1]Hebei Med Univ, Hosp 2, Dept Endocrinol, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Li Gui-Zhi,Liu Jia-Yin,Zhou Hong.Ferroptosis: A novel therapeutic target for diabetic cardiomyopathy[J].WORLD JOURNAL OF DIABETES.2025,16(6):doi:10.4239/wjd.v16.i6.104665.
APA:
Li, Gui-Zhi,Liu, Jia-Yin&Zhou, Hong.(2025).Ferroptosis: A novel therapeutic target for diabetic cardiomyopathy.WORLD JOURNAL OF DIABETES,16,(6)
MLA:
Li, Gui-Zhi,et al."Ferroptosis: A novel therapeutic target for diabetic cardiomyopathy".WORLD JOURNAL OF DIABETES 16..6(2025)